Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...
If the European Commission decides to grant sales of the medicine, it will be the first Alzheimer's medicine available in the ...
Europe's medicines watchdog partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease ...
As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback